Document is current
Any future updates will be listed below
-
Authors
Amirian, Mohammadreza
Chevalley, Arthur
Asiain, María Martín
Klein, Ran
DeKemp, Robert
Moulton, Eric
Prior, John O.
Kamani, Christel H.
Jreige, Mario https://orcid.org/0000-0003-3918-150X
Depeursinge, Adrien
-
Funding
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (205320_219430)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (205320_219430)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (205320_219430)
Swiss Cancer Research Foundation (KFS-5549-02-2022-R)
Lundin Family Brain Tumour Research Centre at CHUV
Hasler Stiftung (MSxplain 21042)
- License Information
-
More Information
Article History
Received: 5 January 2026
Accepted: 15 May 2026
First Online: 28 May 2026
Declarations
Ethics approval and consent to participate: The study was approved by the Cantonal Ethics Commission (CER-VD, PB_2018-01513) and conducted according to the Declaration of Helsinki.
Consent for publication: Not applicable.
Competing interests: R.D.K. and R.K. receives royalty revenues from Rubidium-82 PET technologies licensed to Jubilant DraxImage. E.M. is an employee at Jubilant DraxImage Inc.
